Advertisement.
Advertisement.
Advertisement
Advertisement.
SHPH Shuttle Pharmaceuticals Holdings Inc
2,404
| Market Cap | $7.01M |
| Volume | 156,803.00 |
| 52-Wk High | $0.945 |
| 52-Wk Low | $0.35 |
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
Globe Newswire•4 months ago
Webcasted presentation to take place at 3:10pm ETGAITHERSBURG, Md., April 03, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage...
Share to Feed
MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...
Globe Newswire•4 months ago
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update PR Newswire GAITHERSBURG, Md., March 21, 2024 GAITHERSBURG, Md., March 21...
PR Newswire•4 months ago
MIAMI, March 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...
Globe Newswire•5 months ago
MIAMI, March 05, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 68th Emerging Growth Conference on March 6 & 7, 2024. The...
Globe Newswire•5 months ago
Webcast presentation to take place at 11:25am ETROCKVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty...
Globe Newswire•5 months ago
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering Shuttle Pharma Announces Its Intent to Pursue a Rights Offering PR Newswire ROCKVILLE, Md., Feb. 13, 2024 ROCKVILLE, Md., Feb. 13, 2024...
PR Newswire•5 months ago
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners...
PR Newswire•6 months ago
Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma Shuttle Pharmaceuticals Receives FDA Approval to...
PR Newswire•7 months ago